nasdaq:kpti
|
2132519
|
Mar 23rd, 2024 12:00AM
|
Karyopharm Therapeutics Inc.
|
30K
|
407.00
|
Open
|
|
Mar 22nd, 2024 11:49PM
|
Mar 23rd, 2024 06:59PM
|
Karyopharm Therapeutics Inc. (Nasdaq: KPTI) is a commercial-stage pharmaceutical company whose dedication to pioneering novel cancer therapies is fueled by a belief in the extraordinary strength and courage of patients with cancer. As leaders in XPO1 inhibition whose mission is to improve lives and defeat cancer, Karyopharm has created a focused pipeline targeting multiple high, unmet need cancer indications, including multiple myeloma, endometrial cancer, myelofibrosis, and diffuse large B-cell lymphoma (DLBCL).
|
Open
|
oncology, pharmaceutical, biotech, multiplemyeloma, lymphoma, solidtumors, glioblastoma, clinicalresearch, clinicaltrials, research, drugdiscovery, medical, and healthcare
|
Open
|
85 Wells Avenue
|
Newton
|
MA
|
US
|
02459
|
|
Karyopharm Therapeutics
|
Health Care
|
Pharmaceuticals & Biotechnology
|
nasdaq:kpti
|
2132519
|
Mar 22nd, 2024 12:00AM
|
Karyopharm Therapeutics Inc.
|
30K
|
407.00
|
Open
|
|
Mar 21st, 2024 11:40PM
|
Mar 22nd, 2024 06:47PM
|
Karyopharm Therapeutics Inc. (Nasdaq: KPTI) is a commercial-stage pharmaceutical company whose dedication to pioneering novel cancer therapies is fueled by a belief in the extraordinary strength and courage of patients with cancer. As leaders in XPO1 inhibition whose mission is to improve lives and defeat cancer, Karyopharm has created a focused pipeline targeting multiple high, unmet need cancer indications, including multiple myeloma, endometrial cancer, myelofibrosis, and diffuse large B-cell lymphoma (DLBCL).
|
Open
|
oncology, pharmaceutical, biotech, multiplemyeloma, lymphoma, solidtumors, glioblastoma, clinicalresearch, clinicaltrials, research, drugdiscovery, medical, and healthcare
|
Open
|
85 Wells Avenue
|
Newton
|
MA
|
US
|
02459
|
|
Karyopharm Therapeutics
|
Health Care
|
Pharmaceuticals & Biotechnology
|
nasdaq:kpti
|
2132519
|
Mar 21st, 2024 12:00AM
|
Karyopharm Therapeutics Inc.
|
30K
|
407.00
|
Open
|
|
Mar 20th, 2024 11:52PM
|
Mar 21st, 2024 05:31PM
|
Karyopharm Therapeutics Inc. (Nasdaq: KPTI) is a commercial-stage pharmaceutical company whose dedication to pioneering novel cancer therapies is fueled by a belief in the extraordinary strength and courage of patients with cancer. As leaders in XPO1 inhibition whose mission is to improve lives and defeat cancer, Karyopharm has created a focused pipeline targeting multiple high, unmet need cancer indications, including multiple myeloma, endometrial cancer, myelofibrosis, and diffuse large B-cell lymphoma (DLBCL).
|
Open
|
oncology, pharmaceutical, biotech, multiplemyeloma, lymphoma, solidtumors, glioblastoma, clinicalresearch, clinicaltrials, research, drugdiscovery, medical, and healthcare
|
Open
|
85 Wells Avenue
|
Newton
|
MA
|
US
|
02459
|
|
Karyopharm Therapeutics
|
Health Care
|
Pharmaceuticals & Biotechnology
|
nasdaq:kpti
|
2132519
|
Mar 20th, 2024 12:00AM
|
Karyopharm Therapeutics Inc.
|
30K
|
407.00
|
Open
|
|
Mar 20th, 2024 12:28AM
|
Mar 20th, 2024 07:31PM
|
Karyopharm Therapeutics Inc. (Nasdaq: KPTI) is an innovation-driven pharmaceutical company dedicated to the discovery, development, and commercialization of novel first-in-class drugs directed against nuclear export and related targets for the treatment of cancer and other major diseases. Karyopharm's Selective Inhibitor of Nuclear Export (SINE) compounds function by binding with and inhibiting the nuclear export protein XPO1 (or CRM1). Karyopharm’s lead compound, XPOVIO® (selinexor), received accelerated approval from the U.S. Food and Drug Administration (FDA) in July 2019 in combination with dexamethasone as a treatment for patients with heavily pretreated multiple myeloma. In June 2020, XPOVIO was approved by the FDA as a treatment for patients with relapsed or refractory diffuse large B-cell lymphoma. A Marketing Authorization Application for selinexor for patients with heavily pretreated multiple myeloma is also currently under review by the European Medicines Agency. In addition to single-agent and combination activity against a variety of human cancers, SINE compounds have also shown biological activity in models of neurodegeneration, inflammation, autoimmune disease, certain viruses and wound-healing. Karyopharm has several investigational programs in clinical or preclinical development.
|
Open
|
oncology, pharmaceutical, biotech, multiplemyeloma, lymphoma, solidtumors, glioblastoma, clinicalresearch, clinicaltrials, research, drugdiscovery, medical, and healthcare
|
Open
|
85 Wells Avenue
|
Newton
|
MA
|
US
|
02459
|
|
Karyopharm Therapeutics
|
Health Care
|
Pharmaceuticals & Biotechnology
|
nasdaq:kpti
|
2132519
|
Mar 19th, 2024 12:00AM
|
Karyopharm Therapeutics Inc.
|
30K
|
407.00
|
Open
|
|
Mar 18th, 2024 11:28PM
|
Mar 19th, 2024 06:04PM
|
Karyopharm Therapeutics Inc. (Nasdaq: KPTI) is an innovation-driven pharmaceutical company dedicated to the discovery, development, and commercialization of novel first-in-class drugs directed against nuclear export and related targets for the treatment of cancer and other major diseases. Karyopharm's Selective Inhibitor of Nuclear Export (SINE) compounds function by binding with and inhibiting the nuclear export protein XPO1 (or CRM1). Karyopharm’s lead compound, XPOVIO® (selinexor), received accelerated approval from the U.S. Food and Drug Administration (FDA) in July 2019 in combination with dexamethasone as a treatment for patients with heavily pretreated multiple myeloma. In June 2020, XPOVIO was approved by the FDA as a treatment for patients with relapsed or refractory diffuse large B-cell lymphoma. A Marketing Authorization Application for selinexor for patients with heavily pretreated multiple myeloma is also currently under review by the European Medicines Agency. In addition to single-agent and combination activity against a variety of human cancers, SINE compounds have also shown biological activity in models of neurodegeneration, inflammation, autoimmune disease, certain viruses and wound-healing. Karyopharm has several investigational programs in clinical or preclinical development.
|
Open
|
oncology, pharmaceutical, biotech, multiplemyeloma, lymphoma, solidtumors, glioblastoma, clinicalresearch, clinicaltrials, research, drugdiscovery, medical, and healthcare
|
Open
|
85 Wells Avenue
|
Newton
|
MA
|
US
|
02459
|
|
Karyopharm Therapeutics
|
Health Care
|
Pharmaceuticals & Biotechnology
|
nasdaq:kpti
|
2132519
|
Mar 18th, 2024 12:00AM
|
Karyopharm Therapeutics Inc.
|
30K
|
407.00
|
Open
|
|
Mar 17th, 2024 11:49PM
|
Mar 18th, 2024 07:16PM
|
Karyopharm Therapeutics Inc. (Nasdaq: KPTI) is an innovation-driven pharmaceutical company dedicated to the discovery, development, and commercialization of novel first-in-class drugs directed against nuclear export and related targets for the treatment of cancer and other major diseases. Karyopharm's Selective Inhibitor of Nuclear Export (SINE) compounds function by binding with and inhibiting the nuclear export protein XPO1 (or CRM1). Karyopharm’s lead compound, XPOVIO® (selinexor), received accelerated approval from the U.S. Food and Drug Administration (FDA) in July 2019 in combination with dexamethasone as a treatment for patients with heavily pretreated multiple myeloma. In June 2020, XPOVIO was approved by the FDA as a treatment for patients with relapsed or refractory diffuse large B-cell lymphoma. A Marketing Authorization Application for selinexor for patients with heavily pretreated multiple myeloma is also currently under review by the European Medicines Agency. In addition to single-agent and combination activity against a variety of human cancers, SINE compounds have also shown biological activity in models of neurodegeneration, inflammation, autoimmune disease, certain viruses and wound-healing. Karyopharm has several investigational programs in clinical or preclinical development.
|
Open
|
oncology, pharmaceutical, biotech, multiplemyeloma, lymphoma, solidtumors, glioblastoma, clinicalresearch, clinicaltrials, research, drugdiscovery, medical, and healthcare
|
Open
|
85 Wells Avenue
|
Newton
|
MA
|
US
|
02459
|
|
Karyopharm Therapeutics
|
Health Care
|
Pharmaceuticals & Biotechnology
|
nasdaq:kpti
|
2132519
|
Mar 17th, 2024 12:00AM
|
Karyopharm Therapeutics Inc.
|
30K
|
407.00
|
Open
|
|
Mar 17th, 2024 01:25AM
|
Mar 17th, 2024 01:25AM
|
Karyopharm Therapeutics Inc. (Nasdaq: KPTI) is an innovation-driven pharmaceutical company dedicated to the discovery, development, and commercialization of novel first-in-class drugs directed against nuclear export and related targets for the treatment of cancer and other major diseases. Karyopharm's Selective Inhibitor of Nuclear Export (SINE) compounds function by binding with and inhibiting the nuclear export protein XPO1 (or CRM1). Karyopharm’s lead compound, XPOVIO® (selinexor), received accelerated approval from the U.S. Food and Drug Administration (FDA) in July 2019 in combination with dexamethasone as a treatment for patients with heavily pretreated multiple myeloma. In June 2020, XPOVIO was approved by the FDA as a treatment for patients with relapsed or refractory diffuse large B-cell lymphoma. A Marketing Authorization Application for selinexor for patients with heavily pretreated multiple myeloma is also currently under review by the European Medicines Agency. In addition to single-agent and combination activity against a variety of human cancers, SINE compounds have also shown biological activity in models of neurodegeneration, inflammation, autoimmune disease, certain viruses and wound-healing. Karyopharm has several investigational programs in clinical or preclinical development.
|
Open
|
oncology, pharmaceutical, biotech, multiplemyeloma, lymphoma, solidtumors, glioblastoma, clinicalresearch, clinicaltrials, research, drugdiscovery, medical, and healthcare
|
Open
|
85 Wells Avenue
|
Newton
|
MA
|
US
|
02459
|
|
Karyopharm Therapeutics
|
Health Care
|
Pharmaceuticals & Biotechnology
|
nasdaq:kpti
|
2132519
|
Mar 16th, 2024 12:00AM
|
Karyopharm Therapeutics Inc.
|
30K
|
407.00
|
Open
|
|
Mar 15th, 2024 11:19PM
|
Mar 16th, 2024 07:03PM
|
Karyopharm Therapeutics Inc. (Nasdaq: KPTI) is an innovation-driven pharmaceutical company dedicated to the discovery, development, and commercialization of novel first-in-class drugs directed against nuclear export and related targets for the treatment of cancer and other major diseases. Karyopharm's Selective Inhibitor of Nuclear Export (SINE) compounds function by binding with and inhibiting the nuclear export protein XPO1 (or CRM1). Karyopharm’s lead compound, XPOVIO® (selinexor), received accelerated approval from the U.S. Food and Drug Administration (FDA) in July 2019 in combination with dexamethasone as a treatment for patients with heavily pretreated multiple myeloma. In June 2020, XPOVIO was approved by the FDA as a treatment for patients with relapsed or refractory diffuse large B-cell lymphoma. A Marketing Authorization Application for selinexor for patients with heavily pretreated multiple myeloma is also currently under review by the European Medicines Agency. In addition to single-agent and combination activity against a variety of human cancers, SINE compounds have also shown biological activity in models of neurodegeneration, inflammation, autoimmune disease, certain viruses and wound-healing. Karyopharm has several investigational programs in clinical or preclinical development.
|
Open
|
oncology, pharmaceutical, biotech, multiplemyeloma, lymphoma, solidtumors, glioblastoma, clinicalresearch, clinicaltrials, research, drugdiscovery, medical, and healthcare
|
Open
|
85 Wells Avenue
|
Newton
|
MA
|
US
|
02459
|
|
Karyopharm Therapeutics
|
Health Care
|
Pharmaceuticals & Biotechnology
|
nasdaq:kpti
|
2132519
|
Mar 15th, 2024 12:00AM
|
Karyopharm Therapeutics Inc.
|
30K
|
409.00
|
Open
|
|
Mar 15th, 2024 12:44AM
|
Mar 15th, 2024 08:53AM
|
Karyopharm Therapeutics Inc. (Nasdaq: KPTI) is an innovation-driven pharmaceutical company dedicated to the discovery, development, and commercialization of novel first-in-class drugs directed against nuclear export and related targets for the treatment of cancer and other major diseases. Karyopharm's Selective Inhibitor of Nuclear Export (SINE) compounds function by binding with and inhibiting the nuclear export protein XPO1 (or CRM1). Karyopharm’s lead compound, XPOVIO® (selinexor), received accelerated approval from the U.S. Food and Drug Administration (FDA) in July 2019 in combination with dexamethasone as a treatment for patients with heavily pretreated multiple myeloma. In June 2020, XPOVIO was approved by the FDA as a treatment for patients with relapsed or refractory diffuse large B-cell lymphoma. A Marketing Authorization Application for selinexor for patients with heavily pretreated multiple myeloma is also currently under review by the European Medicines Agency. In addition to single-agent and combination activity against a variety of human cancers, SINE compounds have also shown biological activity in models of neurodegeneration, inflammation, autoimmune disease, certain viruses and wound-healing. Karyopharm has several investigational programs in clinical or preclinical development.
|
Open
|
oncology, pharmaceutical, biotech, multiplemyeloma, lymphoma, solidtumors, glioblastoma, clinicalresearch, clinicaltrials, research, drugdiscovery, medical, and healthcare
|
Open
|
85 Wells Avenue
|
Newton
|
MA
|
US
|
02459
|
|
Karyopharm Therapeutics
|
Health Care
|
Pharmaceuticals & Biotechnology
|
nasdaq:kpti
|
2132519
|
Mar 14th, 2024 12:00AM
|
Karyopharm Therapeutics Inc.
|
30K
|
409.00
|
Open
|
|
Mar 13th, 2024 11:17PM
|
Mar 14th, 2024 12:14PM
|
Karyopharm Therapeutics Inc. (Nasdaq: KPTI) is an innovation-driven pharmaceutical company dedicated to the discovery, development, and commercialization of novel first-in-class drugs directed against nuclear export and related targets for the treatment of cancer and other major diseases. Karyopharm's Selective Inhibitor of Nuclear Export (SINE) compounds function by binding with and inhibiting the nuclear export protein XPO1 (or CRM1). Karyopharm’s lead compound, XPOVIO® (selinexor), received accelerated approval from the U.S. Food and Drug Administration (FDA) in July 2019 in combination with dexamethasone as a treatment for patients with heavily pretreated multiple myeloma. In June 2020, XPOVIO was approved by the FDA as a treatment for patients with relapsed or refractory diffuse large B-cell lymphoma. A Marketing Authorization Application for selinexor for patients with heavily pretreated multiple myeloma is also currently under review by the European Medicines Agency. In addition to single-agent and combination activity against a variety of human cancers, SINE compounds have also shown biological activity in models of neurodegeneration, inflammation, autoimmune disease, certain viruses and wound-healing. Karyopharm has several investigational programs in clinical or preclinical development.
|
Open
|
oncology, pharmaceutical, biotech, multiplemyeloma, lymphoma, solidtumors, glioblastoma, clinicalresearch, clinicaltrials, research, drugdiscovery, medical, and healthcare
|
Open
|
85 Wells Avenue
|
Newton
|
MA
|
US
|
02459
|
|
Karyopharm Therapeutics
|
Health Care
|
Pharmaceuticals & Biotechnology
|